0,00
- 8:00
- 9:00
- 11:00
- 13:00
- 15:00
- 17:00
- 20:00
- 22:00
- 0.00
- 0.03
- 0.06
- 0.09
- 0.12
ERTRÄGE
Das Unternehmen zahlt regelmäßig eine Dividende von 85,20 € pro Aktie mit einer Rendite von 76.759,91% – sehr hoch – könnte auf Bewertungsrabatt oder Risiken hindeuten. Die Ausschüttungsquote von 0,00% ist nicht vorhanden. Die Dividende ist stabil und unverändert – das Unternehmen hält verlässlich.
85,20 €
Jährliche Dividende
76.759,91 %
Rendite
0,00 %
Dividenden-Wachstum
0,00 %
Ausschüttungsquote
UNTERNEHMEN
73.000,0 $
Umsatz
-91,03 %
Umsatz-Wachstum
17,4 Mio. $
Nettogewinn
-
105,5 %
ROE -
23.845,2 %
ROS -
76,5 %
ROA -
-36.723,3 %
GPM
-21,6 Mio. $
Operativer Cashflow
16,5 Mio. $
Eigenkapital
42
Mitarbeiter
-
1.738,1 $
Umsatz / MA -
414.452,4 $
Gewinn / MA
KGV
0,22 $KBV
0,24 $KCV
-0,18 $KUV
54,83 $EV/EBITDA
0,12 $EV/EBIT
0,18 $EV/FCF
0,15 $EV/Umsatz
-45,89 $EnterpriseValue
-3,3 Mio. $Eigenkapitalrendite
105,45 %Umsatzrendite
23.845,21 %EBIT-Marge
-25.071,23 %EBITDA-Marge
-36.723,29 %Kapitalumschlag
0,003 $Gesamtkapitalrendite
76,45 %Eigenkapitalquote
0,73 $Fremdkapitalquote
0,27 $Verschuldungsgrad
0,38 $Dyn. Verschuldungsgrad
-0,29 $Sachinvestitionsquote
0,002 $Anlagendeckungsgrad 1
0,42 $Anlagendeckungsgrad 2
0,34 $Liquidität 1. Grades
5,16 $Liquidität 2. Grades
5,16 $Liquidität 3. Grades
6,03 $Dividende pro Aktie
0,00 $Dividendenrendite
0,00 %Ausschüttungsquote
0,00 %Buchwert pro Aktie
2,39 $Cashflow pro Aktie
-3,13 $Stand: 31.03.2023 TTM
Fakten
-
Sitz
USA
-
Hauptsitz
Salt Lake City
-
Börsengang
16.08.1999
-
Ausstehende Aktien
6,91 Mio.
-
Mitarbeiter
42
-
Währung
USD
-
Sektor
Gesundheitswesen
-
Industrie
Biotechnology
-
Börse
NASDAQ
-
Ticker
PTE
-
Webseite
Aktie
Unternehmensinfos
PolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; PTE 11000, an allogenic, biologically active dressing for use in wound care and aesthetics to accelerate healing of skin; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.
PolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; PTE 11000, an allogenic, biologically active dressing for use in wound care and aesthetics to accelerate healing of skin; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.